fire flow cell thrash
consensu sale guid y/i
sale yoy vs consensu led
sequenc consum sale yoy array anoth strong qtr
well consum servic yoy driven dtc consum
genom test sequenc servic grew yoy mainten contract cdx
develop deal w/ biopharma instrument revenu ahead
est top-lin beat favor mix flow margin adj
gm yoy adj opm well-ahead estim
non-gaap ep vs our/street est beat
outlook rais novaseq hit stride
bulk beat came seq consum name novaseq nextseq
seq servic strength seq servic benefit somewhat collabor w/
pharma bm loxo oncolog cdx develop seq consum strength
even back stock order china custom ahead
tariff speak underli long-term revenu driver grow diversifi
instal base dna sequenc well robust demand varieti custom
academ clinic pop-seq consum pharma much
predict recur revenu stream seq consum repres
overal compani sale all-tim high compar sale recent
seq instrument sale vs given healthi end-
market demand think ilmn rais guid could still conserv
sale growth vs prior management also rais ep guid
mdpt prior despit healthi level oper expens spend
increment d/commerci spend drive futur growth
rais est po see least sale growth
expect sale yoy ep
reiter buy rate sequenc demand clearli continu
grow across end-market custom rais po still
base dcf analysi assum wacc termin growth rate
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit prospect due wide
adopt compani innov genet
analysi tool strong competit posit
impress forward-look product market
strategi although macro competit risk
remain believ compani recent
launch near-term pipelin help
remain forefront
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim consid
justifi given attract long-term outlook genom market compani
technolog leadership new product cycl increas penetr fast-
grow clinic appli market
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit integr
issu grow concern data privaci slower-than-expect uptak new
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
